Active Ingredient History
Flupentixol (INN), also known as flupenthixol, marketed under brand names such as Depixol and Fluanxol is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1965 by Lundbeck. In addition to single drug preparations, it is also available as flupentixol/melitracen—a combination product containing both melitracen and flupentixol . Flupentixol is not approved for use in the United States. It is, however, approved for use in the UK, Australia, Canada, Russian Federation, South Africa, New Zealand, Philippines, Iran, Germany, and various other countries. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Antipsychotic Agents (Phase 4)
Anxiety Disorders (Phase 3)
Central Nervous System Diseases (Phase 4)
Cocaine-Related Disorders (Phase 2)
Compliance (Phase 4)
Dementia (Phase 3)
Depression (Phase 4)
Dyspepsia (Phase 4)
Emotions (Phase 4)
Flupenthixol (Phase 4)
Globus Sensation (Phase 3)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 1/Phase 2)
Metabolic Syndrome (Phase 4)
Nervous System Diseases (Phase 4)
Olanzapine (Phase 4)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Quetiapine Fumarate (Phase 4)
Schizophrenia (Phase 4)
Substance-Related Disorders (Phase 2)
Tinnitus (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue